Issue 11, 2022

Discovery of antipsychotic loxapine derivatives against intracellular multidrug-resistant bacteria

Abstract

The emergence and spread of multidrug-resistant bacteria highlight the need for new antibacterial interventions. A screening of 24 newly synthesized dibenzoxazepines identified a small molecule compound, SW14, with potent inhibitory activity against intracellular multidrug-resistant and fluoroquinolone-resistant strains of S. typhimurium in macrophages and epithelial cells. Moreover, intra-macrophagic Salmonella typhi, Yersinia enterocolitica, and Listeria monocytogenes and methicillin-resistant Staphylococcus aureus are also susceptible to SW14. Overall, our findings suggest that SW14 has a broad-spectrum activity against intracellular bacteria.

Graphical abstract: Discovery of antipsychotic loxapine derivatives against intracellular multidrug-resistant bacteria

Supplementary files

Article information

Article type
Research Article
Submitted
14 Jun 2022
Accepted
02 Aug 2022
First published
11 Aug 2022

RSC Med. Chem., 2022,13, 1361-1366

Discovery of antipsychotic loxapine derivatives against intracellular multidrug-resistant bacteria

H. Lin, Y. Wu, C. Hsu, M. Lin, L. Chen, C. Shiau and H. Chiu, RSC Med. Chem., 2022, 13, 1361 DOI: 10.1039/D2MD00182A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements